{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T07:55:59Z","timestamp":1792828559513,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,11,22]],"date-time":"2017-11-22T00:00:00Z","timestamp":1511308800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007311","name":"Deutsche Kinderkrebsstiftung","doi-asserted-by":"publisher","award":["DKS 2014.13"],"award-info":[{"award-number":["DKS 2014.13"]}],"id":[{"id":"10.13039\/501100007311","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s00431-017-3042-5","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T22:42:38Z","timestamp":1511304158000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis"],"prefix":"10.1007","volume":"177","author":[{"given":"Anika","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Adelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Lohle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Claviez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann L.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,22]]},"reference":[{"key":"3042_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s11102-008-0149-8","volume":"12","author":"SV Acharya","year":"2009","unstructured":"Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, Shah NS (2009) Clinical profile and long term follow up of children and adolescents with prolactinomas. Pituitary 12:186\u2013189","journal-title":"Pituitary"},{"key":"3042_CR2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/0091217415582172","volume":"49","author":"M Atmaca","year":"2015","unstructured":"Atmaca M, Korkmaz S, Ustundag B, Ozkan Y (2015) Increased serum prolactin in borderline personality disorder. Int J Psychiatry Med 49:169\u2013175","journal-title":"Int J Psychiatry Med"},{"key":"3042_CR3","first-page":"1123","volume":"25","author":"G Catli","year":"2012","unstructured":"Catli G, Abaci A, Altincik A, Demir K, Can S, Buyukgebiz A, Bober E (2012) Hyperprolactinemia in children: clinical features and long-term results. J Pediatr Endocrinol Metab 25:1123\u20131128","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3042_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"Ciccarelli A, Daly AF, Beckers A (2005) The epidemiology of prolactinomas. Pituitary 8:3\u20136","journal-title":"Pituitary"},{"key":"3042_CR5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s11102-015-0658-1","volume":"18","author":"O Cohen-Inbar","year":"2015","unstructured":"Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP (2015) Gamma knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18:820\u2013830","journal-title":"Pituitary"},{"key":"3042_CR6","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85:2247\u20132252","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR7","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1210\/jcem.83.8.5001","volume":"83","author":"A Colao","year":"1998","unstructured":"Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, Sarnacchiaro F, Facciolli G, Lombardi G (1998) Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83:2777\u20132780","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR8","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao A, Vitale G, Cappabianca P, Briganti F, Ciccarelli A, De Rosa M, Zarrilli S, Lombardi G (2004) Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab 89:1704\u20131711","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95:43\u201351","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR10","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4274\/jcrpe.v3i2.14","volume":"3","author":"E Eren","year":"2011","unstructured":"Eren E, Yapici S, Cakir ED, Ceylan LA, Saglam H, Tarim O (2011) Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 3:65\u201369","journal-title":"J Clin Res Pediatr Endocrinol"},{"key":"3042_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000236081","volume":"72","author":"HL Fideleff","year":"2009","unstructured":"Fideleff HL, Boquete HR, Suarez MG, Azaretzky M (2009) Prolactinoma in children and adolescents. Horm Res 72:197\u2013205","journal-title":"Horm Res"},{"key":"3042_CR12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000357673","volume":"81","author":"F Guaraldi","year":"2014","unstructured":"Guaraldi F, Storr HL, Ghizzoni L, Ghigo E, Savage MO (2014) Paediatric pituitary adenomas: a decade of change. Horm Res Paediatr 81:145\u2013155","journal-title":"Horm Res Paediatr"},{"key":"3042_CR13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","volume":"70","author":"N Herring","year":"2009","unstructured":"Herring N, Szmigielski C, Becher H, Karavitaki N, Wass JA (2009) Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol 70:104\u2013108","journal-title":"Clin Endocrinol"},{"key":"3042_CR14","volume-title":"Endotext","author":"JA Jane Jr","year":"2000","unstructured":"Jane JA Jr, Laws ER Jr (2000) Surgical treatment of pituitary adenomas. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Koch C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO (eds) Endotext. MDText.com, Inc., South Dartmouth"},{"key":"3042_CR15","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars M, Delgado V, Holman ER, Feelders RA, Smit JW, Romijn JA, Bax JJ, Pereira AM (2008) Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J Clin Endocrinol Metab 93:3348\u20133356","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR16","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94:2428\u20132436","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR17","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1210\/jc.2009-0999","volume":"94","author":"A Klibanski","year":"2009","unstructured":"Klibanski A (2009) Dopamine agonist therapy in prolactinomas: when can treatment be discontinued? J Clin Endocrinol Metab 94:2247\u20132249","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1530\/EJE-07-0248","volume":"158","author":"J Kreutzer","year":"2008","unstructured":"Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158:11\u201318","journal-title":"Eur J Endocrinol"},{"key":"3042_CR19","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1210\/jcem.84.12.6240","volume":"84","author":"S Kunwar","year":"1999","unstructured":"Kunwar S, Wilson CB (1999) Pediatric pituitary adenomas. J Clin Endocrinol Metab 84:4385\u20134389","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-08-0213","volume":"159","author":"P Lancellotti","year":"2008","unstructured":"Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, Pierard L, Beckers A (2008) Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol 159:1\u20135","journal-title":"Eur J Endocrinol"},{"key":"3042_CR21","doi-asserted-by":"crossref","first-page":"R213","DOI":"10.1530\/EJE-14-0013","volume":"170","author":"D Maiter","year":"2014","unstructured":"Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170:R213\u2013R227","journal-title":"Eur J Endocrinol"},{"key":"3042_CR22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96:273\u2013288","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR23","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s11102-012-0401-0","volume":"16","author":"HL Muller","year":"2013","unstructured":"Muller HL (2013) Childhood craniopharyngioma. Pituitary 16:56\u201367","journal-title":"Pituitary"},{"issue":"3","key":"3042_CR24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1210\/er.2013-1115","volume":"35","author":"HL Muller","year":"2014","unstructured":"Muller HL (2014) Craniopharyngioma. Endocr Rev 35(3):513\u2013543","journal-title":"Endocr Rev"},{"key":"3042_CR25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-2001-16855","volume":"213","author":"HL Muller","year":"2001","unstructured":"Muller HL, Bueb K, Bartels U, Roth C, Harz K, Graf N, Korinthenberg R, Bettendorf M, Kuhl J, Gutjahr P, Sorensen N, Calaminus G (2001) Obesity after childhood craniopharyngioma\u2014German multicenter study on pre-operative risk factors and quality of life. Klin Padiatr 213:244\u2013249","journal-title":"Klin Padiatr"},{"key":"3042_CR26","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00381-005-1166-9","volume":"21","author":"HL Muller","year":"2005","unstructured":"Muller HL, Gebhardt U, Faldum A, Emser A, Etavard-Gorris N, Kolb R, Sorensen N (2005) Functional capacity and body mass index in patients with sellar masses\u2014cross-sectional study on 403 patients diagnosed during childhood and adolescence. Childs Nerv Syst 21:539\u2013545","journal-title":"Childs Nerv Syst"},{"key":"3042_CR27","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K (2008) Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metab 93:4721\u20134727","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR28","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/jcem-59-5-941","volume":"59","author":"SE Sauder","year":"1984","unstructured":"Sauder SE, Frager M, Case GD, Kelch RP, Marshall JC (1984) Abnormal patterns of pulsatile luteinizing hormone secretion in women with hyperprolactinemia and amenorrhea: responses to bromocriptine. J Clin Endocrinol Metab 59:941\u2013948","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","volume":"12","author":"S Vallette","year":"2009","unstructured":"Vallette S, Serri K, Rivera J, Santagata P, Delorme S, Garfield N, Kahtani N, Beauregard H, Aris-Jilwan N, Houde G, Serri O (2009) Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12:153\u2013157","journal-title":"Pituitary"},{"key":"3042_CR30","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, Mockel J, Lamberigts G, Petrossians P, Coremans P, Mahler C, Stevenaert A, Verlooy J, Raftopoulos C, Beckers A (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84:2518\u20132522","journal-title":"J Clin Endocrinol Metab"},{"key":"3042_CR31","doi-asserted-by":"crossref","first-page":"R11","DOI":"10.1530\/EJE-08-0365","volume":"159","author":"A Wakil","year":"2008","unstructured":"Wakil A, Rigby AS, Clark AL, Kallvikbacka-Bennett A, Atkin SL (2008) Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 159:R11\u2013R14","journal-title":"Eur J Endocrinol"},{"key":"3042_CR32","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/2046-4053-1-33","volume":"1","author":"AT Wang","year":"2012","unstructured":"Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW, Fernandez-Balsells MM, Bagatto A, Coto-Yglesias F, Carey J, Elraiyah TA, Erwin PJ, Gandhi GY, Montori VM, Murad MH (2012) Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst Rev 1:33","journal-title":"Syst Rev"},{"key":"3042_CR33","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2265.1984.tb03467.x","volume":"21","author":"SJ Winters","year":"1984","unstructured":"Winters SJ, Troen P (1984) Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin Endocrinol 21:257\u2013263","journal-title":"Clin Endocrinol"},{"key":"3042_CR34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1055\/s-2008-1046486","volume":"208","author":"JE Wolff","year":"1996","unstructured":"Wolff JE, Daumling E, Dirksen A, Dabrock A, Hartmann M, Jurgens H (1996) Munster Heidelberg abilities scale\u2014a measuring instrument for global comparison of illness sequelae. Klin Padiatr 208:294\u2013298","journal-title":"Klin Padiatr"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00431-017-3042-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-3042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-017-3042-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T17:35:22Z","timestamp":1514828122000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00431-017-3042-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,22]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["3042"],"URL":"https:\/\/doi.org\/10.1007\/s00431-017-3042-5","relation":{},"ISSN":["0340-6199","1432-1076"],"issn-type":[{"value":"0340-6199","type":"print"},{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,22]]}}}